Caremax, INC 8-K filings

CareMax, Inc. and its affiliates, currently operating as debtors-in-possession, have filed monthly operating reports for November 2024 with the U.S. Bankruptcy Court.

CareMax, currently undergoing Chapter 11 bankruptcy, has finalized a $122 million debtor-in-possession financing agreement to support its operations.

CareMax has entered into a stalking horse agreement with ClareMedica for the sale of its core clinic assets as part of a prearranged Chapter 11 bankruptcy plan.

CareMax has reached agreements to sell its management services organization and core centers assets through a prearranged Chapter 11 plan supported by its secured lenders.

CareMax has obtained an extension on its loan agreement and drawn $3 million for short-term operations while exploring strategic alternatives to address its financial challenges.

CareMax, Inc. has obtained an extension on a previously disclosed debt waiver and amendment period from its lenders until November 11, 2024.

CareMax, Inc. has obtained an extension on a previously disclosed debt waiver and amendment period from its lenders until November 4, 2024.

CareMax, Inc. has drawn $5 million from its existing credit facility to cover short-term operating expenses while exploring various strategic alternatives to address its capital needs.

CareMax, Inc. has obtained an extension on a previously disclosed waiver of certain debt defaults and an amendment period through October 28, 2024.

CareMax, Inc. has obtained an extension on a previously disclosed debt waiver from its lenders, pushing the deadline to October 14, 2024.

CareMax has obtained an extension on its debt waiver and secured an additional $4 million loan, while also exploring strategic alternatives to avoid potential bankruptcy.

CareMax, Inc. received a delisting notice from Nasdaq due to its market value of publicly held shares falling below the required minimum, and appointed a new independent director.

CareMax, Inc. has obtained an extension on a previously disclosed waiver of certain debt defaults until September 30, 2024.

CareMax has obtained an extension on a previously disclosed debt waiver from its lenders, pushing the deadline to September 16, 2024.

CareMax, Inc. has obtained an extension on a previously disclosed waiver of certain debt defaults until September 10, 2024, providing additional time for negotiations with lenders.

CareMax, Inc. has obtained an extension on a previously disclosed waiver of certain debt defaults until September 3, 2024.

CareMax, Inc. has drawn $3 million from its existing credit facility to cover short-term operating expenses while exploring strategic alternatives to address its capital needs.

CareMax, Inc. has obtained a limited waiver extension on its credit agreement through August 22, 2024, to avoid certain defaults.

CareMax reported a 12% year-over-year decrease in total revenue for the second quarter of 2024, alongside a significant net loss, despite a slight increase in Medicare Advantage membership.

CareMax, Inc. has entered into an agreement for $20 million in new term loans and amended its existing credit agreement, including a waiver of certain defaults until August 15, 2024.

CareMax, Inc. has obtained a limited extension on a waiver for certain credit agreement defaults through July 10, 2024.

CareMax, Inc. has obtained a limited waiver extension on its credit agreement through July 8, 2024, to avoid certain defaults.

CareMax, Inc. has obtained a limited extension on a waiver for certain defaults under its Credit Agreement until June 28, 2024.

CareMax, Inc. has obtained a limited extension on a waiver for certain defaults under its Credit Agreement until June 24, 2024.

CareMax, Inc. has appointed Paul Rundell as Chief Restructuring Officer, effective June 10, 2024, to navigate financial and operational challenges.

CareMax Inc. has entered into a Fourth Amendment to its Credit Agreement, extending a waiver of certain defaults and modifying covenants through June 17, 2024.

CareMax reported a 34% year-over-year increase in revenue for the first quarter of 2024, but also a net loss of $43.4 million and is exploring strategic options to improve liquidity.

CareMax announced its fourth quarter and full year 2023 financial results, showing a significant net loss due to non-cash goodwill impairment, while also reporting growth in Medicare Advantage membership and total revenue for the year.

CareMax, Inc. has completed a one-for-thirty reverse stock split of its Class A common stock, effective January 31, 2024, to increase the per-share trading price.

CareMax has announced a 1-for-30 reverse stock split of its Class A common stock, effective January 31, 2024, to regain compliance with Nasdaq's minimum bid price requirement.